Neuphoria Therapeutics (NEUP) Operating Leases (2020 - 2025)

Neuphoria Therapeutics (NEUP) posted quarterly Operating Leases of $19322.0 for Q1 2025, down 61.21% quarter-over-quarter from $49818.0 in Q4 2024.

Neuphoria Therapeutics (NEUP) Operating Leases (2020 - 2025) Analysis & Trends

Neuphoria Therapeutics (NEUP) has reported Operating Leases for 6 consecutive years, with $19322.0 the latest figure, recorded in Q1 2025.

In Q1 2025, Operating Leases changed N/A year-over-year to $19322.0; the TTM figure through Mar 2025 stood at $19322.0 (changed N/A YoY), while the FY2024 annual figure was $117628.0, down 50.95% from the prior year.
Operating Leases fell to $19322.0 in Q1 2025 per NEUP's latest filing, from $49818.0 in the prior quarter.
Across five years, Operating Leases topped out at $534128.0 in Q2 2021 and bottomed at $19322.0 in Q1 2025.
Historically, Operating Leases has averaged $204903.9 across 5 years, with a median of $117628.0 in 2024.
Annual changes were most pronounced in 2021 — Operating Leases jumped 3103.76% — and 2024, when it sank 51.35%.
Neuphoria Therapeutics' Operating Leases stood at $534128.0 in 2021, then declined by 28.45% to $382188.6 in 2022, then plunged by 36.74% to $241774.0 in 2023, then slumped by 79.39% to $49818.0 in 2024, then tumbled by 61.21% to $19322.0 in 2025.
Business Quant data shows NEUP's Operating Leases at $19322.0 in Q1 2025, $49818.0 in Q4 2024, and $89469.0 in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Neuphoria Therapeutics	21.37 Mn	1.93 Mn	-

Download Data